Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia The safety profile of subcutaneous allergen immunotherapy in children with asthm...
Journal Information
Vol. 45. Issue 6.
Pages 541-548 (November - December 2017)
Download PDF
More article options
Vol. 45. Issue 6.
Pages 541-548 (November - December 2017)
Original Article
DOI: 10.1016/j.aller.2017.04.002
The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China
J.-L. Liua,1, W.-X. Ningb,1, S.-X. Lia, Y.-C. Xua, L. Wua, Y.-S. Wanga, X.-F. Xua, Y. Jianga, Y.-J. Shenga, Y.-L. Zhoua, J.-H. Wanga, L.-F. Tanga, Z.-M. Chena,
Corresponding author

Corresponding author.
a Department of Respiratory Medicine, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
b Department of Dermatology, Guangxing Hospital, Zhejiang Chinese Medical University, Hangzhou, China
This item has received
Article information
Full Text
Download PDF
Figures (1)
Tables (7)
Table 1. Asthma severity scoring system.
Table 2. Treatment schedule of standardized immunotherapy.
Table 3. Basic information of patients.
Table 4. Prevalence of SRs in children and adolescents.
Table 5. Prevalence of SRs between mild and moderate asthma.
Table 6. Administered rescue medications for systemic reactions.
Table 7. Risk factors for SRs to SCIT analysed by logistic regression.
Show moreShow less

The aim of the current study is to evaluate the prevalence, severity and possible risk factors of systemic reactions (SRs) to subcutaneous allergen immunotherapy (SCIT) in children and adolescents with asthma in Hangzhou, east China's Zhejiang province.


From January 2011 to December 2016, this survey analysed the SCIT-related SRs involving 429 patients (265 children and 134 adolescents) affected by allergic asthma. Recorded data included demographics, diagnosis, patient statuses, pulmonary function testing results before and after each injection, allergen dosage, and details of SRs.


All patients finished the initial phase and six patients withdrew during the maintenance phase. There were 2.59% (328/12,655) SRs in all injections (3.28% in children and 1.47% in adolescents); 15.62% (67/429) patients experienced SRs (18.49% children and 10.98% adolescents). There were 54.57% SRs of grade 1; 42.37% SRs of grade 2; 3.05% SRs of grade 3; and no grades 4 or grade 5 SRs occurred in patients. Most reactions were mild, and were readily controlled by immediate emergency treatment. There was no need for hospitalisation. The occurrence of SRs was significantly higher in children than that in adolescents (p<0.01). A higher ratio of SRs was found among patients with moderate asthma.


This retrospective survey showed that properly-conducted SCIT was a safe treatment for children and adolescents with asthma in Hangzhou, East China. Children and patients with moderate asthma may be prone to develop SRs.

Subcutaneous allergen immunotherapy
Systemic reactions
Dermatophagoides pteronyssinus


These are the options to access the full texts of the publication Allergologia et Immunopathologia

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Allergologia et Immunopathologia

Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.